尼可地尔在急性心肌梗死中的研究进展

doi:10.3969/j.issn.1000-8535.2018.01.031

广州医药 ›› 2018, Vol. 49 ›› Issue (1): 105-109.DOI: 10.3969/j.issn.1000-8535.2018.01.031

尼可地尔在急性心肌梗死中的研究进展

李展鸽¹, 韩薇薇², 张峻瑞¹, 刘小红¹, 蒋凯¹, 葛利军³

1 西北民族大学 (兰州 730000);
2 宁夏医科大学(银川 750000);
3 宁夏回族自治区人民医院(西北民族大学附属一院)(银川 750000)

收稿日期:2017-09-25 出版日期:2018-01-20 发布日期:2021-12-01
通讯作者: 葛利军,E-mail:gelijun1958@ 126.com

Advancement in the study of nicorandil in acute myocardial infarction

LI Zhange¹, HAN Weiwei¹, ZHANG Junrui¹, LIU Xiaohong¹, JIANG Kai¹, GE Lijun²

1 Northwest Minzu University,Lanzhou 730000,China;
2 Ningxia Medical University, Yinchuan 750000,China;
3 Ningxia People' Hospital,Yinchuan 750000,China

Received:2017-09-25 Online:2018-01-20 Published:2021-12-01

摘要/Abstract

摘要： 尼可地尔是一种ATP敏感型钾离子通道开放剂,同时兼有类硝酸酯作用,具有舒张冠脉和外周血管及通过缺血预适应对心脏起保护作用等双重功效,主要用于抗心绞痛的治疗。介于尼可地尔这种特殊结构及其作用机制能否降低急性心肌梗死患者PCI术后无复流的发生率及改善临床预后,目前临床研究仍在探索中。现就尼可地尔的作用机制、模拟的药物预适应作用、及综合作用与急性心肌梗死的关系做一综述,评估尼可地尔作为辅助药物在AMI行介入治疗中的作用及临床预后,指导临床用药。

关键词: 尼可地尔, 急性心肌梗死, 无复流

Abstract: Nicorandil is an ATP-sensitive potassium (K-ATP) channel opener, meanwhile has an effect like nitrate, has dual actions including coronary and peripheral vasodilatation and cardioprotective effects through ischemic preconditioning, mainly for the treatment of anti-angina. Whether the specific structure of nicorandil and its mechanism can reduce the incidence of no-reflow in patients with acute myocardial infarction (AMI) after PCI and improve the clinical prognosis, the current clinical research is still under investigation. We will expound mechanisms of nicorandil, drug preconditioning and its comprehensive effect. The role of nicorandil in the interventional therapy of AMI was reviewed to guide clinical medication.

Key words: Nicorandil, Acute myocardial infarction, No-reflow

李展鸽, 韩薇薇, 张峻瑞, 刘小红, 蒋凯, 葛利军. 尼可地尔在急性心肌梗死中的研究进展[J]. 广州医药, 2018, 49(1): 105-109.

LI Zhange, HAN Weiwei, ZHANG Junrui, LIU Xiaohong, JIANG Kai, GE Lijun. Advancement in the study of nicorandil in acute myocardial infarction[J]. Guangzhou Medical Journal, 2018, 49(1): 105-109.

参考文献

[1] YANG J, ZHANG J, CUI W, et al. Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention [J]. Anadolu Kardiyol Derg, 2015, 15(2): 125-31.
[2] WANG Z Q, CHEN M X, LIU D L, et al. The effect on myocardial perfusion and clinical outcome of intracoronary nicorandil injection prior to percutaneous coronary intervention in ST-segment elevation myocardial infarction [J]. Zhonghua Xin Xue Guan Bing Za Zhi, 2017, 45(1): 26-33.
[3] THE IONA STUDY GROUP.Effect of nicorandil on coronary events in patients with stable angina: the impact of nicorandil in Angina (IONA) randomised trial[J]. Lancet, 2002,359(9314):1269-1275.
[4] AMBROSIO G, KOMAJDA M, MUGELLI A, et al. Management of stable angina: A commentary on the European Society of Cardiology guidelines [J]. Eur J Prev Cardiolog, 2016, 23(13): 1401-1412.
[5] ASENSIO-LÓPEZ M C, SOLER F, PASCUAL-FIGAL D, et al. Doxorubicin-induced oxidative stress: The protective effect of nicorandil on HL-1 cardiomyocytes [J]. PloS One, 2017, 12(2): e0172803.
[6] ZALEWSKI J, NESSLER J. The endogenous cardioprotection during reperfusion in acute myocardial infarction [J]. Kardiologia Polska, 2011,69 Suppl(3):67-74.
[7] CHEN Z, CHEN X, LI S, et al. Nicorandil improves myocardial function by regulating plasma nitric oxide and endothelin-1 in coronary slow flow[J]. Coron Artery Dis,2015,26(2):114-120.
[8] RAVINDRAN S, MURALI J, AMIRTHALINGAM S K, et al. Vascular calcification abrogates the nicorandil mediated cardio-protection in ischemia reperfusion injury of rat heart [J]. Vascul Pharmacol, 2017(89):31-38.
[9] WU H, YE M, YANG J, et al. Nicorandil protects the heart from ischemia/reperfusion injury by attenuating endoplasmic reticulum response-induced apoptosis through pi3k/akt signaling pathway[J]. Cell Physiol Biochem, 2015,35(6):2320-2332.
[10] LI W, WU N, SHU W, et al. Pharmacological preconditioning and postconditioning with nicorandil attenuates ischemia/reperfusion-induced myocardial necrosis and apoptosis in hypercholesterolemic rats [J]. Exp Ther Med, 2015, 10(6): 2197-2205.
[11] SMITH K J, CHADBURN A J, ADOMAVICIENE A, et al. Coronary spasm and acute myocardial infarction due to a mutation (V734I) in the nucleotide binding domain 1 of ABCC9[J]. Int J Cardiol, 2013,168(4):3506-3513.
[12] KIKUCHI Y, YASUDA S, AIZAWA K, et al. Enhanced Rho-kinase activity in circulating neutrophils of patients with vasospastic angina: a possible biomarker for diagnosis and disease activity assessment[J]. J Am Coll Cardiol, 2011,58(12):1231-1237.
[13] RODRIGUEZ-PASCUAL F, BUSNADIEGO O, LAGARES D, et al. Role of endothelin in the cardiovascular system[J]. Pharmacol Res,2011,63(6):463-472.
[14] MURRY CE, JENNINGS RB, REIMER KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium[J]. Circulation,1986,74(5):1124-1136.
[15] ZHAO Z Q, CORVERA J S, HALKOS M E, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning[J]. Am J Physiol Heart Circ Physiol, 2003,285(2):H579-588.
[16] PANG Z, ZHAO W, YAO Z. Cardioprotective effects of nicorandil on coronary heart disease patients undergoing elective percutaneous coronary intervention [J]. Med Sci Monit, 2017, 15(23):2924-2930.
[17] WANG Y Y, LI T, LIU Y W, et al. Effect of the ischemic post-conditioning on the prevention of the cardio-renal damage in patients with acute ST-segment elevation myocardial infarction after primary percutaneous coronary intervention[J]. Zhonghua Xin Xue Guan Bing Za Zhi, 2017, 45(4): 277-282.
[18] YAMADA K, ISOBE S, ISHII H, et al. Impacts of nicorandil on infarct myocardium in comparison with nitrate: assessed by cardiac magnetic resonance imaging[J]. Heart and vessels,2016,31(9):1430-1437.
[19] YANG J, ZHANG J, CUI W, et al. Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention[J]. Anadolu Kardiyol Derg,2015,15(2):125-131.
[20] KOSTIC J, DJORDJEVIC-DIKIC A, DOBRIC M, et al. The effects of nicorandil on microvascular function in patients with ST segment elevation myocardial infarction undergoing primary PCI[J]. Cardiovasc Ultrasound,2015(13):26.
[21] KIM S J, KIM W, WOO J S, et al. Effect of myocardial protection of intracoronary adenosine and nicorandil injection in patients undergoing non-urgent percutaneous coronary intervention: a randomized controlled trial[J]. Int J Cardiol, 2012,158(1):88-92.
[22] HWANG J, LEE H C, KIM B W, et al. Effect on periprocedural myocardial infarction of intra-coronary nicorandil prior to percutaneous coronary intervention in stable and unstable angina[J]. Int J Cardiol, 2013,62(2):77-81.
[23] WU M, HUANG Z, XIE H, ZHOU Z. Nicorandil in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: A systematic review and meta-analysis[J]. PloS One, 2013,8(10):e78231.
[24] LEE H L, CHANG P C, CHOU C C, et al. Blunted proarrhythmic effect of nicorandil in a Langendorff-perfused phase-2 myocardial infarction rabbit model[J]. Pacing Clin Electrophysiol, 2013,36(2):142-151.
[25] ITO N, NANTO S, DOI Y, et al. High index of microcirculatory resistance level after successful primary percutaneous coronary intervention can be improved by intracoronary administration of nicorandil[J]. Circ J, 2010,74(5):909-915.
[26] ISHII H, ICHIMIYA S, KANASHIRO M, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction[J]. Circulation, 2005,112(9):1284-1288.
[27] YANG M J, LEE H C, LEE H W, et al. Effect of nicorandil on clinical outcomes in patients with ST-segment elevation and non-ST-segment elevation myocardial infarction: based on the Korea Acute Myocardial Infarction Registry (KAMIR)[J]. Int J Cardiol,2013,168(5):4868-4869.

尼可地尔在急性心肌梗死中的研究进展

Advancement in the study of nicorandil in acute myocardial infarction

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 4

编辑推荐

Metrics

本文评价

[1]	陈希妍, 张建新, 牛丽丹, 孔令宇, 杨飞云, 石金河. 氯吡格雷联合低分子肝素对老年心肌梗死患者血清血脂及炎性因子的影响[J]. 广州医药, 2021, 52(2): 46-49.
[2]	叶飘, 雷晓明. 入院首次中性粒细胞/淋巴细胞比值与急性心肌梗死患者院内主要不良心血管事件发生的相关性研究[J]. 广州医药, 2018, 49(5): 13-17.
[3]	李晓彬, 刘卫明, 齐建雄. 远程早期干预模式在STEMI患者直接经皮冠状动脉介入中的应用疗效[J]. 广州医药, 2018, 49(4): 94-95.
[4]	全楚杰, 翟永新, 梁国泉, 陈以明, 伍文锋. 不同血运重建策略对急性心肌梗死合并多支血管病变患者的疗效对比[J]. 广州医药, 2018, 49(2): 80-83.